

SANDU PHARMACEUTICALS LIMITED
 REGD. OFFICE: PLOT NOS. 25, 26, 29 & 30, PILERNE INDUSTRIAL ESTATE,
 MARRA, SALIGAO, BARDEZ GOA- 403 511.
STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER ENDED 30/09/2015

(In Lacs)						
Particulars	3 months ended 30/09/2015	3 months ended 30/06/2015	Corresponding 3 months ended 30/09/2014 the previous year	Year to date figures for current period ended 30/09/2015	Year to date figures for current period ended 30/09/2014	Previous year ended 31/03/2015
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
(Refer Notes Below)						
1 Income from continuing operations						
(a) Net sales/income from operations (Net of excise duty)	1,171.93	991.57	1091.68	2,163.50	2,016.18	4,440.30
Less: Trade Discount	125.61	107.99	115.87	233.60	213.32	480.14
	1,046.32	883.58	975.81	1,929.90	1,802.86	3,960.16
(b) Other operating income						
Total income from operations (net)	1,046.32	883.58	975.81	1,929.90	1,802.86	3,960.16
2 Expenses						
(a) Cost of materials consumed	252.83	121.78	61.65	374.61	241.99	676.18
(b) Purchases of traded goods	518.27	514.39	355.77	1,032.66	600.20	1,382.38
(c) Changes in inventories of finished goods, work-in-progress, traded goods & Stock in Transit	(182.16)	(187.77)	134.12	(369.93)	163.68	143.87
(d) Employee benefits expense	97.39	104.64	92.96	202.03	178.39	368.99
(e) Depreciation and amortisation expense	11.66	13.32	15.66	24.98	30.99	57.46
(f) Other expenses	304.03	269.84	258.64	573.87	489.00	1,145.08
Total expenses	1,002.02	836.20	918.80	1,838.22	1,704.24	3,773.96
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	44.30	47.38	57.01	91.68	98.63	186.20
4 Other income	2.80	3.46	1.83	6.26	4.29	13.69
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	47.10	50.84	58.84	97.94	102.92	199.89
6 Finance costs	42.84	34.08	37.28	76.92	70.93	137.02
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	4.26	16.76	21.56	21.02	31.99	62.87
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	4.26	16.76	21.56	21.02	31.99	62.87
10 Tax expense	3.26	3.62	6.75	6.88	6.17	21.51
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	1.00	13.14	14.81	14.14	25.82	41.36
12 Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	
13 Net Profit / (Loss) for the period (11 + 12)	1.00	13.14	14.81	14.14	25.82	41.36
14 Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest *	-	-	0.00	-	-	-
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	1.00	13.14	14.81	14.14	25.82	41.36
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	708.10	708.10	708.10	708.10	708.10	708.10
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						
19 i Earnings per share, (before extraordinary items) (of 10 /- each) (not annualised):	0.01	0.19	0.21	0.20	0.36	0.58
(a) Basic						
(b) Diluted						
19 ii Earnings per share (after extraordinary items) (of 10 /- each) (not annualised):						
(a) Basic						
(b) Diluted						




PART II						
A PARTICULARS OF SHAREHOLDING						
1	Public shareholding					
	- Number of shares	3,895,310.00	3,895,310.00	3,895,310.00	3,895,310.00	3,895,310.00
	- Percentage of shareholding	55.01	55.01	55.01	55.01	55.01
2	Promoters and Promoter Group Shareholding					
a)	Pledged / Encumbered					
	- Number of shares					
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)					
	- Percentage of shares (as a % of the total share capital of the company)					
b)	Non - encumbered					
	- Number of shares	3,185,690.00	3,185,690.00	3,185,690.00	3,185,690.00	3,185,690.00
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	44.99	44.99	44.99	44.99	44.99
Particulars						
B INVESTOR COMPLAINTS						
3 months ended (30/09/2015)						
	Pending at the beginning of the quarter					NIL
	Received during the quarter					NIL
	Disposed of during the quarter					NIL
	Remainng unresolved at the end of the quarter					NIL

Notes to Accounts

1. The Auditors have conducted Limited Review of the financial results for the quarter ended September 30, 2015. The Unaudited Financial results have been recommended by the audit committee at its meeting held on November 14, 2015 and Approved by the Board of Directors at its meeting held on November 14, 2015

For SANDU PHARMACEUTICALS LIMITED



UMESH B SANDU
MANAGING DIRECTOR
DIN- 01132141
PLACE: MUMBAI
DATE: 14th November, 2015



Statement of Assets and Liabilities

Particulars		As at 30/09/2015 (Audited)	As at 31/03/2015 (Audited)
A			
EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share Capital		708.10	708.10
(b) Employee Stock options outstanding		0.00	0.00
(c) Reserves and surplus		1,120.62	1,106.48
Sub-totals - Shareholders' funds		1,828.72	1,814.58
2 Minority Interest			
		0.00	0.00
3 Non-current liabilities			
(a) Other long term liabilities		106.02	119.46
(b) Long term provisions		101.04	100.16
Sub-totals - Non-current liabilities		207.06	219.62
4 Current liabilities			
(a) Trade payables		430.14	1,068.18
(b) Other current liabilities		246.15	624.33
(c) Short term provisions		198.41	245.51
(d) Short term borrowings		1,000.20	209.16
Sub-totals - Current liabilities		1,874.90	2,147.18
TOTAL - EQUITY AND LIABILITIES		3,909.68	4,151.38
B			
ASSETS			
1 Non-current assets			
(a) Fixed assets		819.59	835.71
(b) Capital Work in Progress		0.00	0.00
(c) Non-current investments		71.53	69.74
(d) Long term loans and advances		0.00	0.00
Sub-total - Non-current assets		891.12	905.45
2 Current assets			
(a) Current investments		0.00	0.00
(b) Inventories		1,652.01	1,267.80
(c) Trade receivables		640.50	655.90
(d) Cash and cash equivalents		73.26	113.33
(e) Short term loans and advances		652.79	908.90
(f) Other current assets		0.00	0.00
Sub-totals - Current assets		3,018.56	3,245.93
TOTAL - ASSETS		3,909.68	4,151.38
		0.00	0.00



JOSHI JOSHI & CO.
CHARTERED ACCOUNTANTS

SHREE MAHAVIR CHAMBER, 3RD FLOOR, 1/3, BANAJI STREET, FORT, MUMBAI - 400 001. TEL: 2204 0265 FAX: 2282 8849
M. M. JOSHI, B.COM., F.C.A. Email: joshijoshico@yahoo.co.in

Limited Review Report


We have reviewed the accompanying statement of unaudited financial results of **SANDU PHARMACEUTICALS LIMITED** for the period ended 30/09/2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2400, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with stock exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Joshi Joshi & Co.
Chartered Accountants
(FRN: 104393w)


(M. M. Joshi)
Proprietor
M.No-42466 of 89

Mumbai

Date: 14/11/2015